Home > Topics > Apixaban


January 10, 2012

Apixaban (manufacturer’s designation BMS-562247-01, tradename Eliquis) is a compound being investigated as an anticoagulant. It is a direct factor Xa inhibitor. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban. It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Categories: Topics
%d bloggers like this: